The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Beglynor     1-cyclohexyl-3-[4-[2-(7- methoxy-4,4...

Synonyms: Beglynora, Glurenorm, glikvidon, glycvidon, Gliquidona, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Glurenorm

 

Psychiatry related information on Glurenorm

  • 3. Tetraethylammonium (TEA; 1-5 microg per mouse i.c.v.), apamin (10 ng per mouse i.c.v.), charybdotoxin (1 microg per mouse i.c.v.), gliquidone (3 microg per mouse i.c.v.) and glibenclamide (1 microg per mouse i.c.v.), administered 20 min before the training session, prevented the potassium channel opener-induced amnesia [5].
 

High impact information on Glurenorm

 

Chemical compound and disease context of Glurenorm

 

Biological context of Glurenorm

 

Anatomical context of Glurenorm

 

Associations of Glurenorm with other chemical compounds

  • Without causing significant changes in cellular levels of cyclic adenosine monophosphate (cAMP), the addition of either glibenclamide or gliquidone to isolated rat hepatocytes caused a transient dose- and Ca(2+)-dependent activation of glycogen phosphorylase [19].
  • Effects of gliquidone on D-glucose metabolism in rat pancreatic islets depend on hexose concentration [20].
  • Immunohistochemical localization of islets of Langerhans of streptozotocin (65 mg/kg, ip) induced diabetic + glurenorm (10 mg/kg, po) treated female albino rats revealed increase in number of beta cells and insulin immunoreactivity of beta cells [21].
  • We describe insulin binding and insulin-mediated RNA synthesis on seven human fibroblasts strains in culture initiated from skin biopsies in the presence of three oral antidiabetic agents, Metformin, Gliquidone, and a non-sulfonylurea antidiabetic drug (B X DF 591 ZW), which belong to different chemical classes [22].
  • The hypoglycaemic sulphonylurea gliquidone and glibenclamide exerted a partial uncoupling effect on mitochondrial respiration of liver under in vitro conditions using various citrate cycle intermediates as substrates [14].
 

Gene context of Glurenorm

  • 6. The reversal potential of the anoxic hyperpolarization was unaffected by tetrodotoxin (TTX) but was significantly altered by application of the ATP-sensitive K+ channel (KATP) blocker gliquidone [23].
  • Application of gliquidone additionally resulted in a significantly smaller hypoxia-induced decline in paired-pulse inhibition [23].
  • The effect of gliquidone, an ATP-dependent K+ (KATP) channel blocker, on morphine-induced hypermotility in mice was studied [24].
  • After 6 but not 1 month of gliquidone therapy we also found an increase in the activity of hexokinase in circulating mononuclear leukocytes [2].
  • We concluded that gliquidone is an effective oral hypoglycemic agent for treating patients with NIDDM [25].
 

Analytical, diagnostic and therapeutic context of Glurenorm

References

  1. Effect of gliquidone on insulin binding to rabbit erythrocytes. de Gasparo, M., Hostetter, G., Desaulles, P.A. J. Endocrinol. (1983) [Pubmed]
  2. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. Bonora, E., Moghetti, P., Querena, M., Zenere, M., Cacciatori, V., Tosi, F., Travia, D., Zoppini, G., Muggeo, M. J. Endocrinol. Invest. (1992) [Pubmed]
  3. Gliquidone contributes to improvement of type 2 diabetes mellitus management : a review of pharmacokinetic and clinical trial data. Malaisse, W.J. Drugs in R&D. (2006) [Pubmed]
  4. Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere. Selvaag, E. Photodermatology, photoimmunology & photomedicine. (1996) [Pubmed]
  5. Influence of potassium channel modulators on cognitive processes in mice. Ghelardini, C., Galeotti, N., Bartolini, A. Br. J. Pharmacol. (1998) [Pubmed]
  6. Antiaggregatory activity of hypoglycaemic sulphonylureas. Siluk, D., Kaliszan, R., Haber, P., Petrusewicz, J., Brzozowski, Z., Sut, G. Diabetologia (2002) [Pubmed]
  7. Extrapancreatic action of the sulphonylurea gliquidone: post-receptor effect on insulin-stimulated glycogen synthesis in rat hepatocytes in primary culture. Rinninger, F., Kirsch, D., Häring, H.U., Kemmler, W. Diabetologia (1984) [Pubmed]
  8. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Scarsi, M., Podvinec, M., Roth, A., Hug, H., Kersten, S., Albrecht, H., Schwede, T., Meyer, U.A., Rücker, C. Mol. Pharmacol. (2007) [Pubmed]
  9. Effect of potassium channel modulators in mouse forced swimming test. Galeotti, N., Ghelardini, C., Caldari, B., Bartolini, A. Br. J. Pharmacol. (1999) [Pubmed]
  10. A short period of hypoxia produces a rapid and transient rise in [K+]e in rat hippocampus in vivo which is inhibited by certain K(+)-channel blocking agents. Zetterström, T.S., Vaughan-Jones, R.D., Grahame-Smith, D.G. Neuroscience (1995) [Pubmed]
  11. Potentiation of the insulinotropic and hypoglycemic action of gliquidone by succinic acid esters. García-Martínez, J.A., Villanueva-Peñacarrillo, M.L., Valverde, I., Björkling, F., Malaisse, W.J. Eur. J. Pharmacol. (1997) [Pubmed]
  12. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. von Nicolai, H., Brickl, R., Eschey, H., Greischel, A., Heinzel, G., König, E., Limmer, J., Rupprecht, E. Arzneimittel-Forschung. (1997) [Pubmed]
  13. Evidence for more than one binding site for sulfonylureas in insulin-secreting cells. Verspohl, E.J., Ammon, H.P., Mark, M. J. Pharm. Pharmacol. (1990) [Pubmed]
  14. Interference of the sulphonylurea antidiabeticum gliquidone with mitochondrial bioenergetics in the rat under in vitro conditions. Somogyi, J., Vér, A., Trója, G., Végh, E., Bühler, C., Hatfaludi, F., Csermely, P., Popović, S. Acta physiologica Hungarica. (1995) [Pubmed]
  15. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin. Sridevi, S., Chauhan, A.S., Chalasani, K.B., Jain, A.K., Diwan, P.V. Die Pharmazie. (2003) [Pubmed]
  16. The non-sulfonylurea moiety of gliquidone mimics the effects of the parent molecule on pancreatic B-cells. Garrino, M.G., Meissner, H.P., Henquin, J.C. Eur. J. Pharmacol. (1986) [Pubmed]
  17. Sulfonylurea effects on acid and pepsinogen secretion in isolated rabbit gastric glands. Del Valle, J.C., Olea, J., Pereda, C., Gutiérrez, Y., Felíu, J.E., Rossi, I. Eur. J. Pharmacol. (1998) [Pubmed]
  18. Extrapancreatic action of sulphonylureas: effect of gliquidone on insulin and glucagon binding to rat liver plasma membranes. Bachmann, W., Böttger, I., Haslbeck, M., Mehnert, H. Eur. J. Clin. Invest. (1979) [Pubmed]
  19. Sulfonylureas activate glycogen phosphorylase and increase cytosolic free-Ca2+ levels in isolated rat hepatocytes. López-Alarcón, L., Melián, E., Muñoz-Alonso, M.J., Guijarro, C., Boscá, L., Felíu, J.E. Metab. Clin. Exp. (1993) [Pubmed]
  20. Effects of gliquidone on D-glucose metabolism in rat pancreatic islets depend on hexose concentration. Picton, S., Malaisse-Lagae, F., Malaisse, W.J. Res. Commun. Mol. Pathol. Pharmacol. (1998) [Pubmed]
  21. Effect of glurenorm on immunohistochemical changes in pancreatic beta cells of rats in experimental diabetes. Koyuturk, M., Ozsoy-Sacan, O., Bolkent, S., Yanardag, R. Indian J. Exp. Biol. (2005) [Pubmed]
  22. Three different classes of oral antidiabetic drugs do not increase insulin binding and insulin-induced RNA synthesis in human fibroblast cultures. Frorath, B., Dreyer, M., Rüdiger, H.W. Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie. (1985) [Pubmed]
  23. Hypoxia-induced functional alterations in adult rat neocortex. Luhmann, H.J., Heinemann, U. J. Neurophysiol. (1992) [Pubmed]
  24. Gliquidone, an ATP-dependent K+ channel antagonist, antagonizes morphine-induced hypermotility. Ocaña, M., Del Pozo, E., Baeyens, J.M. Eur. J. Pharmacol. (1993) [Pubmed]
  25. The efficacy and safety of gliquidone in Thai diabetics. Nitiyanant, W., Sriussadaporn, S., Deerochanawong, C., Ngawngamrat, S., Benjasuratwong, Y., Patanaungkul, S. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. (1997) [Pubmed]
  26. Improved insulin receptor assay: effects of an antidiabetic sulphonylurea on liver membrane insulin receptors from obese hyperglycaemic mice. Greenstein, B.D. Br. J. Pharmacol. (1979) [Pubmed]
  27. Diabetic control with gliquidone--a short acting sulphonylurea. Borthwick, L.J., Wilson, S. Eur. J. Clin. Pharmacol. (1984) [Pubmed]
  28. Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Yanardag, R., Ozsoy-Sacan, O., Orak, H., Ozgey, Y. Drug and chemical toxicology. (2005) [Pubmed]
 
WikiGenes - Universities